DBV Technologies SA (DBVT) is a pioneering biopharmaceutical company headquartered in Montrouge, France, focused on revolutionizing food allergy treatment through its proprietary Viaskin™ technology platform. As a clinical-stage organization, DBV is dedicated to developing non-invasive epicutaneous immunotherapies aimed at promoting allergen desensitization, with a primary focus on peanut allergies. The company is currently advancing a robust pipeline through a series of clinical trials, positioning itself as a leader in addressing significant unmet medical needs in allergy management while striving to improve patient quality of life.
Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began…
Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the…
